SellYourAIData
Get a free valuation Contact

AI Data Deal TrackerDeal brief

×

Wiley licenses Cochrane and more than 400 journals and books to OpenEvidence

Wiley will license a portfolio of scientific and medical content, including the Cochrane Database of Systematic Reviews, to OpenEvidence's clinical AI platform. No fees or duration were disclosed.

HOBOKEN, N.J., March 3, 2026. Wiley announced a partnership with OpenEvidence to license a portfolio of scientific and medical content to the physician-facing AI platform.1

Terms of the deal

The portfolio includes the Cochrane Database of Systematic Reviews and Cochrane Clinical Answers, plus more than 400 Wiley journals and books across medical specialties. OpenEvidence will reference the content within its evidence layer and cite it to its sources.1 The companies said the partnership may expand into society relationships, global expansion and other healthcare and life sciences uses.1

The release does not disclose licensing fees, payment structure, contract value or duration.1

Background

OpenEvidence has been signing content agreements with medical publishers. It announced multi-year deals with NEJM Group in February 2025 and the JAMA Network in June 2025, and a subscription agreement with Springer Nature in August 2026.2

For Wiley, the deal adds to a set of AI partnerships that includes Amazon Web Services, Perplexity and Anthropic. Wiley reported $49.1 million of AI license revenue for fiscal 2026.3 Wiley's CEO, Matt Kissner, said the agreement puts Wiley's catalog into the platform where clinical decisions happen.1

What it means for data sellers

Vertical AI companies pay for content that makes their answers verifiable. A smaller seller with a deep specialist dataset can approach these buyers directly instead of general-purpose AI labs. The seller should expect to be cited and to provide structured access, and should plan for the buyer to sign several competitors in the same field.

How the deal came together

  1. Wiley packaged a medical portfolio. The package includes Cochrane Database of Systematic Reviews, Cochrane Clinical Answers and more than 400 Wiley journals and books across medical specialties.
  2. OpenEvidence adds it to its evidence layer. The content is referenced within OpenEvidence's evidence layer and cited back to its sources.
  3. Physicians use it at the point of care. Clinicians asking questions in OpenEvidence get answers that can draw on the licensed material.
  4. Both sides left room to expand. The companies said they may explore society relationships, global expansion and other healthcare uses.

Takeaways for companies with data

  • Specialist content with clear provenance, such as systematic reviews, is what vertical AI products want.
  • Citation back to the source is a standard condition in medical content deals.
  • Publishers can sell the same corpus to several vertical tools.

Sources

Every numbered reference above points to an entry here. Figures come from these pages as of the date shown at the top of the article. Where a source reports a number it got from unnamed people, the text says so.

  1. Wiley and OpenEvidence Partner to Deliver Trusted Research to Physicians at the Point of Care (Wiley, March 2026)
  2. Springer Nature and OpenEvidence announce agreement (Springer Nature, August 2026)
  3. Wiley reports $49.1M in AI licensing revenue for fiscal 2026 (SellYourAIData deal tracker, citing Wiley's 10-K, April 2026)

###

About the AI Data Deal Tracker

SellYourAIData tracks publicly reported sales and licenses of data to AI companies, with the price, terms and sources for each. Entries are checked against public reporting and updated as deals change. SellYourAIData was not involved in this deal. To ask what your company's data could sell for, get a free valuation. To report a deal, contact us.